Ice Bear Therapeutics
Revolutionizing Insulin Manufacturing
Revolutionizing insulin manufacturing making it faster, cheaper and more sustainable


Our Mission
Technology
Advanced mammalian cell lines technology paired with highly efficient continuous manufacturing bioreactors that requires a fraction of resources compared to existing methods.
Past
- Porcine and Bovine Pancreases
- Grinding, extraction

1901
- Extremely low yield
- Animal insulin > anaphylactic shock 1901
Present
- Bacterial, fungal microorganism
- Cell lysis, extraction

1960
- Very low yield
- Labor, resource & time intensive
Future
- Mammalian Cells
- Continuous Secretion

2030
- Very high yield
- ULTRA EFFICIENT with minimal resources

Products
Biosimilar Lispro
( fast-acting insulin )
Biosimilar Lispro: Our first candidate will be biosimilar Lispro which is a fast-acting insulin taken before meals to provide immediate support for patients with type 1 diabetes. We have forecasted its availability for commercial release in 2030.




Biosimilar Glargine
( Long-acting insulin )
Our next candidate starting evaluation is biosimilar Glargine, a long-acting insulin.
Biosimilar Glargine
( Long-acting insulin )
Our next candidate starting evaluation is biosimilar Glargine, a long-acting insulin.


About Us
Ice Bear Therapeutics is headquartered in Seattle, Washington in the United States of America. We have global manufacturing partners in New Jersey and India. Ice Bear Therapeutics is a registered Social Purpose Company. We believe by lowering our cost of goods and significantly increasing supply, we can meet the demand needs of our customers with reasonable pricing.


Why “Ice Bear”?
Since our children were very young, they have owned stuffed polar bears; and these white, fluffy companions have been a big part of their lives. Our kids have traveled with them, held them in difficult times, and used them as a source of comfort and reassurance. They are, in a very real sense, part of our family. Even as our children and their bears have aged, our kids still love them, and they have given them a nickname: “Icy.” Our family roots are in Germany, and in German, “icy,” in this context, connotes “cute” or “endearing,” and those attributes are universal: Children all over the world find warmth and love in their stuffed bears.
That is why we named our company Ice Bear Therapeutics. We are developing a new process for manufacturing insulin to ensure that the comfort and reassurance that insulin brings to type 1 patients will always be there. We understand the challenges that type 1 diabetes brings for all patients, but children with type 1 face unique physical and emotional challenges. If you’ve witnessed first-hand a child who needs insulin, you will understand why we are so committed to bringing critical innovation to the insulin manufacturing process. Our goal is to ensure that the supply of insulin is dependable, enduring, and life-sustaining. And most important, we want to ensure it’s always there when a child needs it.
Team
A Management & Scientific team committed to solving insulin availability for the future long term diabetic communities.

Christian Pfleger, PhD
Scientist & Pharmacist for 24y
- pharmaceutical sciences and biotech.
- Expert in drug development, molecular immunology, and biosimilar manufacturing.
- Proven track record in leading innovative biotech projects and scaling operations.

Andreas Pfleger, MSc
Pharmacist for 14y Sauter Apotheke
- 14 years in pharmacy and clinical management.
- Expertise in drug commercialization, pharmaceutical operations, and managing high-performing teams.
- Previously led pharmaceutical production and regulatory approvals.

Brian Tagami, BSc
20 Years Enterprise Sales & Marketing
- Over 20 years of experience in enterprise sales and marketing.
- Specializes in strategic marketing and biotech sales channels.
- Extensive background in consumer health and pharmaceutical sales growth.

Steve Hilbert, MBA
18 years Banking & Biotechnology
- 18 years in banking and biotechnology advisory.
- Expertise in capital formation, investment strategies, and biotech commercialization.
- Former Vice President at JP Morgan and Charles Schwab, specializing in biotech investments.
Advisory Board Members

James Hirsch
is an esteemed bestselling author and has raised significant awareness for one of America’s fastest-growing health issues, Diabetes. His book “Cheating Destiny, Living with Diabetes” brings much needed awareness to the issues facing millions of people battling this fast-growing disease.

Irl Hirsch, MD
Dr. Irl Hirsch is one of the foremost experts in Diabetes and has been serving patients for over 30 years. His insights as a clinician who sees patients firsthand will be tremendously valuable as we develop our biosimilar, affordable insulin products.
All of our team members have a personal connection to diabetes and the communities that rely on insulin. We will not fail.
Advisory Board Members
James Hirsch


James Hirsch
is an esteemed bestselling author and has raised significant awareness for one of America’s fastest-growing health issues, Diabetes. His book “Cheating Destiny, Living with Diabetes” brings much needed awareness to the issues facing millions of people battling this fast-growing disease.
James Hirsch
is an esteemed bestselling author and has raised significant awareness for one of America’s fastest-growing health issues, Diabetes. His book “Cheating Destiny, Living with Diabetes” brings much needed awareness to the issues facing millions of people battling this fast-growing disease.
